NextFin News - Intuitive Surgical raised its full-year 2026 procedure growth outlook on Tuesday, signaling that the post-pandemic recovery in elective surgeries has found a second wind in the United States and Europe. The Sunnyvale-based robotics pioneer now expects da Vinci procedure volumes to grow between 15% and 17% for the year, a notable upward revision from the 13% to 15% range provided just three months ago. The announcement, delivered alongside first-quarter results that comfortably beat Wall Street estimates, suggests that the company’s next-generation Da Vinci 5 system is gaining traction faster than many analysts had modeled.
Revenue for the first quarter climbed 23% to $1.7 billion, fueled by a 17% surge in total procedures. The growth was particularly pronounced in the Ion endoluminal platform, which saw a 39% jump in usage, while the core da Vinci business grew 16%. This performance comes at a critical juncture for U.S. President Trump’s administration, as medical device manufacturers navigate a shifting trade landscape. Intuitive Surgical executives noted that while global tariff rates remain a variable, the company managed to offset a roughly 1.2% tariff impact on revenue through accretive pricing and a higher mix of premium Da Vinci 5 placements.
The bullish revision stands in contrast to the more cautious tone struck by some industry observers earlier this year. Sohini Mondal, an analyst at Barchart, had previously highlighted concerns regarding margin pressure and a potential moderation in demand as the company transitioned between system generations. Mondal, who typically focuses on quantitative earnings momentum and technical levels, noted that the company’s ability to maintain adjusted gross margins between 67% and 68% despite inflationary headwinds would be the "real test" for management. The first-quarter results suggest that, for now, the efficiency gains from the new hardware are winning out over cost pressures.
However, the optimism is not universal across the sell-side. While 19 of 30 analysts covering the stock maintain "Strong Buy" ratings, a vocal minority remains wary of the company’s premium valuation. These skeptics argue that the current price-to-earnings multiple leaves little room for error if hospital capital budgets tighten or if competitive platforms from Medtronic and Johnson & Johnson begin to erode Intuitive’s dominant market share. This cautious perspective is not yet the consensus, but it reflects a growing debate over whether the "AI connectivity trade" in healthcare has become overextended.
Geographically, the story is one of two speeds. While the U.S. and Europe provided the heavy lifting for the quarter, the outlook for the Asia-Pacific region remains clouded by regulatory shifts and local competition. In Europe, the company’s recent expansion of its investment footprint appears to be paying dividends, with procedure growth there outpacing the global average. The higher revenue per procedure—now approximately $1,880 compared to $1,780 a year ago—reflects both this regional strength and the successful rollout of the Single Port (SP) system in complex urology and gynecology cases.
The company’s ability to raise guidance while navigating a 10% increase in operating expenses underscores a disciplined approach to scaling. Management attributed the lower-than-expected expense growth to the timing of certain R&D projects, a factor that may reverse in the second half of the year. As the Da Vinci 5 becomes a greater proportion of the total installed base, the financial benefits of its integrated digital tools and higher throughput are becoming more visible on the bottom line. The market’s reaction to the guidance raise will likely hinge on whether investors view this as a sustainable acceleration or a temporary peak in the replacement cycle.
Explore more exclusive insights at nextfin.ai.
